



# CANCER CARE AT THE CROSSROADS

 **NY, March 28, 2025**

**A One-Day International Summit on Innovation, Clinical Benefit and Cost**

## Meet the Sponsors



Horizon Blue Cross Blue Shield of New Jersey



**NewYork-  
Presbyterian**



8:15 am to 8:35 am

## Welcome and Opening Remarks

Setting the Stage for the Day



**SOREN GERMER, PHD**

Senior Vice President Genome Technologies  
New York Genome Center



**THOMAS J. LYNCH, JR., MD**

President and Director,  
Fred Hutch Cancer Center



**MIKE MEYER**

President and Founder,  
Meyer Consulting

8:35am to 9:35 am

## Roundtable 1

Cancer Care Through the Lens of Health Plans, Academic Centers, Pharma and Provider Groups



Moderator

**THOMAS J. LYNCH, JR., MD**

President and Director,  
Fred Hutch Cancer Center



Panelist

**RICHARD BARAKAT, MD**

Physician-in-Chief and Executive  
Director, Northwell Health Cancer  
Institute



Panelist

**MARK BERTOLINI**

CEO, Oscar Health,  
Former CEO, Aetna and Bridgewater  
Associates



Panelist

**JOANNE CONROY, MD**

CEO and President, Dartmouth Health,  
Immediate Past Chair,  
American Hospital Association Board



Panelist

**CINDY PERETTIE**

Executive Vice President,  
Kite Pharma

9:40 am to 10:40 am

## Roundtable 2

The Future of Cancer Science



Moderator  
**LILLIAN SIU, MD, FRCP**  
Professor, *University of Toronto*;  
Medical Oncologist, Director, Phase I  
Program, BMO Chair in Precision  
Genomics, *Princess Margaret Cancer  
Centre*



Panelist  
**ALEXANDER EGGERMONT, MD, PhD**  
CSO, *Utrecht University*, Former  
Director, *Gustave Roussy, Paris*



Panelist  
**ANDRE ESTEVA, PhD**  
CEO,  
*ArteraAI*



Panelist  
**ZHEN SU, MD, MBA**  
CEO, *Marengo Therapeutics*



Panelist  
**SUNIL VERMA, MD**  
SVP Global Head of Oncology  
Franchise, *AstraZeneca*

10:40am to 11:00am

## Break

11:00am to 12:00pm

## Roundtable 3

Improving Patient Outcomes Through Innovations in Care Delivery



Moderator  
**EDWARD LICITRA, MD, PhD**  
Chief Executive Officer,  
*Astera Health Partners/Astera  
Cancer*



Panelist  
**NADINE J. BARRETT, PhD**  
Sr. Associate Dean, Community  
Engagement and Research Equity  
*Wake Forest Baptist School of Medicine*  
Chief Engagement Officer  
*Atrium Health Wake Forest Comprehensive  
Cancer Center*



Panelist  
**STEPHEN FRIEDHOFF, MD**  
Senior Vice President, Health Care  
Services,  
*Blue Cross Blue Shield of North  
Carolina*



Panelist  
**ANAEZE OFFODILE, MD, MPH**  
Chief Strategy Officer,  
*Memorial Sloan Kettering Cancer  
Center*



Panelist  
**JEDD WOLCHOK, MD, PhD**  
Meyer Director of the *Sandra and  
Edward Meyer Cancer Center* and  
Professor of Medicine, *Weill Cornell  
Medicine*



1:15pm to 2:25pm

## Roundtable 4

The Challenges Facing Health Plans, Pharma, Providers and Government in Expensive Innovative Cancer Treatments



Moderator  
**JONATHAN ROCKOFF**  
Health Business Editor and Deputy  
Coverage Chief for Health and  
Science, *The Wall Street Journal*



Panelist  
**CLIFFORD HUDIS, MD, FACP, FASCO**  
Chief Executive Officer,  
*American Society of Clinical  
Oncology (ASCO)*



Panelist  
**SAMIR KHFLEIF, MD**  
Director, *Center for Advanced  
Immunotherapy Research,*  
*Georgetown University* and CEO,  
*Georgiamune, Inc*



Panelist  
**MISHELLENE MCKINNEY, MHA, RN, OCN**  
Vice President, Clinical Programs,  
*Kaiser Permanente*



Panelist  
**GLEN TULLMAN**  
Chief Executive Officer,  
*Transcarent*

2:15 pm to 3:15 pm

## Roundtable 5

The Media and Health Policy



Moderator  
**RICHARD SULLIVAN, MD, PhD**  
Director, *Institute for Cancer Policy,*  
Professor of Cancer & Global  
Health, *King's College London*



Panelist  
**DAN GORENSTEIN**  
Founder and Executive Editor,  
*Tradeoffs*



Panelist  
**ROBERT LOBERG, PhD**  
VP, Disease Area Lifecycle Leader,  
*Roche Sequencing Solutions*



Panelist  
**DAVID RHEW, MD**  
Global Chief Medical Officer, VP  
Healthcare, Worldwide Commercial,  
*Microsoft*



Panelist  
**GLEN STETTIN, MD**  
Senior Vice President and Chief  
Innovation Officer,  
*Evernorth/CIGNA*

3:15 pm to 3:45 pm

## Fireside Chat



**KAREN KNUDSEN, MBA, PHD**

Professor Emerita,  
*Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center,*  
Former CEO,  
*American Cancer Society and ACS CAN*



**NORMAN SHARPLESS, MD**

Professor of Cancer Policy and Innovation,  
*UNC-Chapel Hill,*  
Co-CEO, *Jupiter BioVentures,*  
former Director of *NCI* and former acting Commissioner of *FDA*

# Panelist Bios



## **RICHARD BARAKAT, MD**

Physician-in-Chief and Executive Director,  
*Northwell Health Cancer Institute*

Richard Barakat is an internationally recognized surgeon and clinical investigator who was Chief of the Gynecology Service at Memorial Sloan Kettering from 2001 to 2013 and held the Ronald O. Perelman Chair in Gynecologic Surgery. Dr. Barakat was the lead investigator on several influential clinical trials at MSK, including a study to compare the benefits of laparoscopic versus standard surgery for patients with endometrial cancer and was the lead investigator on an NIH funded national study evaluating symptomatic lower-extremity lymphedema in women undergoing lymphadenectomy for cervical, uterine and vulvar cancer. Dr. Barakat is author or co-author of more than 340 peer-reviewed articles and numerous textbook chapters and was the lead editor of *Principles and Practice of Gynecologic Oncology*, one of the leading texts in the field.

In addition, he served as a member and examiner for the American Board of Obstetrics and Gynecology and for five years served as a director of the Division of Gynecologic Oncology. He was President of the Society of Gynecologic Oncology from 2013 to 2014 and past President of the International Gynecologic Cancer Society (2014-2016). From 2013 -2017, he served as Director of the MSK regional care network and Cancer Alliance.

In 2018 Dr. Barakat joined Northwell Health to lead all cancer services and research and serves as professor of Obstetrics and Gynecology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.



## **NADINE BARRETT, PhD**

Senior Associate Dean, Community Engagement and Research Equity  
*Wake Forest Baptist School of Medicine*  
Chief Engagement Officer  
*Atrium Health Wake Forest Comprehensive Cancer Center*

Dr. Nadine J. Barrett is a Professor in the Department of Social Sciences and Health Policy in the Division of Public Health Sciences and the inaugural Senior Associate Dean of Community Engagement and Equity in Research at Wake Forest School of Medicine, she is Associate Director of Community Outreach and Engagement for Wake Forest Comprehensive Cancer Center, the Clinical Translational Science Institute and the Maya Angelou Center for Health Equity. Prior to joining Wake Forest, Dr. Barrett served 13 years in senior leadership roles at Duke University, as the Founding Director of both the Duke Center for Equity in Research and the nationally awarded, Duke Cancer Institute's Office of Health Equity. She is also President of the national Association of Cancer Care Centers, in Washington DC.

A medical sociologist by training, Dr. Barrett is a health disparities researcher, expert equity strategist, and a nationally recognized leader in facilitating authentic community, healthcare, and academic partnerships to advance health equity. She develops multi-level interventions to address implicit bias, structural and systemic racism, and inequities that limit access to quality research and trustworthy health care among underserved and marginalized populations. Dr. Barrett brings an equity lens to her work and collaborations to enhance healthcare systems, close the disparities gap in health outcomes, and increase diverse and broad representation in research participation and the research workforce.



## **MARK BERTOLINI**

CEO, *Oscar Health*,  
Former CEO,  
*Aetna and Bridgewater Associates*

Mark T. Bertolini is the CEO of Oscar Health, a healthcare technology company focused on making a healthier life accessible and affordable for all. Previously, he was Co-CEO of Bridgewater Associates, the world's largest hedge fund. Prior, Mark served as Chairman and CEO of Aetna Inc., where he transformed the company from a traditional insurer to a consumer-focused healthcare provider. He led Aetna until its \$69 billion acquisition by CVS Health in 2018, after which he served as a Director at CVS Health. Before Aetna, Mark held executive roles at Cigna, NYLCare Health Plans, and was CEO of SelectCare, Inc. He is also a director at Verizon Communications, Thrive Global, and the FIDELCO Guide Dog Foundation.



## JOANNE CONROY, MD

CEO and President, *Dartmouth Health*,  
Immediate Past Chair,  
*American Hospital Association Board*

Joanne M. Conroy, MD, has led Dartmouth Health as chief executive officer and president since 2017, overseeing the management of the state's only academic health system and largest private employer in a complex and rapidly evolving healthcare landscape.

Under Conroy's leadership the system's flagship hospital, Dartmouth Hitchcock Medical Center in Lebanon, NH, is regularly ranked as the #1 hospital in New Hampshire by U.S. News & World Report.

Conroy also has moved Dartmouth Health to continue broadening its service to New Hampshire and Vermont communities through partnerships and collaborations in both states. The Dartmouth Health system now includes four hospitals and a home health agency, and a longstanding, strong relationship with the Geisel School of Medicine at Dartmouth continues to provide key academic and research collaborations to train the next generation of physicians.

Conroy has long been a vocal advocate for increasing the role of women in leadership and is often singled out as a role model for other women who aspire to become leaders and agents for positive change in healthcare.

Conroy was named to the American Hospital Association's Board of Trustees in 2019, and in 2022 was named Chair-Elect Designate, to serve as chair of the American Hospital Association. On January 1, 2024, Conroy became chair of the American Hospital Association Board and will serve as the Immediate Past Chair through December 2025.

In December 2022, Conroy was ranked #18 on Modern Healthcare magazine's list of "100 Most Influential People in Healthcare". Other recent national and regional awards and honors of note include being named to Becker's Hospital Review's "Top 113 Great Leaders in Health care" list and the 2021 Citizen of the Year by the New Hampshire Union Leader.

Conroy received her undergraduate degree in chemistry from Dartmouth College and earned her medical degree at the Medical University of South Carolina. She is board certified with the American Board of Anesthesiologists.



## ALEXANDER EGGERMONT, MD, PhD

CSO, *Utrecht University*  
Former Director, *Gustave Roussy*

Past Director General of the Gustave Roussy Cancer Institute & Emeritus Full Professor of Oncology(2012-20)(Classe Exceptionnelle) at the Paris-Sud University in Paris, France. Emeritus Full Professor of Surgical Oncology (2003-2016) as well as Endowed Professor of International Networking in Cancer Research (2011-2020) at Erasmus University MC Rotterdam. He holds the Joseph Maisin Chair in Oncology at Catholic University of Louvain in Belgium. PhD in tumor immunology at Erasmus University Rotterdam (1987) and is a Fellow of the NCI Surgery Branch, USA.

Specialties: His clinical specialties include immunotherapy, melanoma, sarcoma and general drug development. He is a past Chair of the EORTC Melanoma Group and current Chair of the Adjuvant Therapy Committee EORTC MG. His basic research experience is in tumor immunology, advanced in vivo imaging models, drug development.

Scientific Output: is the author or co-author of > 900 peer-reviewed publications, book chapters and monographs. More than 35 PhD theses have originated in his clinical, translational and basic research programs at the Erasmus University MC Rotterdam. H-Index: 132; > 90.000 citations (Google Scholar)

International Functions:

Deutsche Krebshilfe: Coordinator German CCC Network Program European Academy of Cancer Sciences: President, 2010-2020 Cancer Core Europe President – 2014-2020

ECCO: Past President EORTC: Past President

ASCO: Past Board Member (Surgery Chair) and JCO Editorial Board AACR: Past Deputy Editor of Clinical Cancer Research (2001-2009) European Journal of Cancer: Editor-in-Chief since 2011

Societal Awards:

Legion d'Honneur, France (2015)



## ANDRE ESTEVA, PhD

CEO, *ArteraAI*

Andre Esteve is a researcher and entrepreneur in medical artificial intelligence. He currently serves as CEO of ArteraAI, and was previously Head of Medical AI at Salesforce Research. He has worked at Google Research, Sandia National Labs, GE Healthcare, and has founded four companies.

His research efforts have largely focused on medical AI diagnostics and precision medicine. His publications have made the covers of Nature and Nature Medicine, and have been featured in Cell, The Lancet, NeurlPS, and similar venues. These works have been widely covered by the WSJ, Fortune, BBC, The Economist, and hundreds of other news outlets.

He obtained his PhD in Artificial Intelligence at Stanford, where his research was in deep learning and computer vision, with applications built for dermatology, drug screening, neuroscience, and psychiatry. He finished undergraduate degrees with highest honors in Electrical Engineering and Pure Math from UT-Austin and was awarded Engineering Valedictorian (formally, the Outstanding Scholar-Leader Award).



# Panelist Bios



## **STEPHEN FRIEDHOFF, MD**

Senior Vice President, Health Care Services,  
*Blue Cross Blue Shield of North Carolina*

Dr. Stephen Friedhoff is Senior Vice President, Health Care Services, responsible for relationships with health care providers, medical policy, corporate pharmacy, appeals, care management, and overall leadership of the company's health care division. He also leads the implementation of Blue Cross NC medical cost and care initiatives such as value-based care and other innovative payment models, in addition to supporting programs for independent primary care practices. He is a seasoned executive with more than 20 years of experience in clinical and administrative leadership roles. Most recently, he served as the Chief Clinical Officer for Help at Home, the leading national provider of high quality, person-centered care. The company provides support to the elderly and people with disabilities in their homes and community-based settings.

Prior to his current role, Dr. Friedhoff spent over a decade at Anthem serving in a variety of roles including National Chief Clinical Officer, Senior Vice President of Clinical Operations and Products, Diversified Business Group, Senior Vice President of Clinical Strategy and Programs and Chief Medical Officer of Anthem's Government Business Division. In his role as National Chief Clinical Officer at Anthem, he drove a significant increase in medical cost savings while also improving the effectiveness and consistency of programs during his tenure.

His earlier roles included Regional Medical Director with Independence Blue Cross in Philadelphia, PA and Clinical Faculty and Medical Director at the Virtua Family Medicine Residency Program in Mount Holly, NJ. He continued to practice family medicine in New Jersey until 2015.

Dr. Friedhoff obtained his undergraduate degree at Rensselaer Polytechnic Institute in Troy, NY, and his medical degree at the Rutgers–New Jersey Medical School in Newark, NJ. He completed his family medicine residency at Virtua Memorial Hospital in Mount Holly, NJ where he served as Chief Resident and was the recipient of the New Jersey Resident of the Year Award by the New Jersey Academy of Family Physicians.

He is a certified health insurance executive through America's Health Insurance Plans, a diplomat of the American Academy of Family Physicians and board certified by the American Board of Family Medicine. Dr. Friedhoff holds active medical licenses in New Jersey and Florida and will be pursuing licensing in North Carolina.



## **DAN GORENSTEIN**

Founder and Executive Editor,  
*Tradeoffs*

Dan is the Founder and Executive Editor of Tradeoffs, setting the vision for the organization's journalism and strategy. Before Tradeoffs, he was the senior health care reporter at Marketplace and spent 11 years at New Hampshire Public Radio. He got his start in journalism at the Chicago Reporter, an investigative journal that examines race and class disparities in the Chicago area. Dan's work has earned numerous national awards, including the Society of Professional Journalists Sigma Delta Chi investigative reporting award. He is based in Philadelphia.



## **CLIFFORD HUDIS, MD, FACP, FASCO**

Chief Executive Officer,  
*American Society of Clinical Oncology (ASCO)*

Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice Chair of its Conquer Cancer Foundation. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society's 50th anniversary year (2013-14).

Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board's strategic goals through research, education, and promotion of the highest quality, equitable patient care by the Society's nearly 50,000 members.



## **SAMIR KHLEIF, MD**

Director,  
*Center for Advanced Immunotherapy Research, Georgetown University and*  
CEO, *Georgiamune, Inc*

Dr. Khleif, MD is an immunologist and immune therapist. His research program is "translational tumor immunology" focused on understanding mechanisms through which the immune system and cancer cells interact and how to overcome tumor tolerance in developing therapeutic approaches. Specifically, his research interests include developing novel immune therapeutics, cancer vaccines and delineating the mechanisms of resistance to immunotherapy.

Prior to transferring his research program to Georgetown University in 2017, Dr. Khleif served as the Director of Georgia Cancer Center, Augusta University. As Director of the Georgia Cancer Center, Dr. Khleif oversaw the development of a large integrated program of basic scientists and clinicians merging the Cancer Center strength in immunology, inflammation and tolerance basic science and immune therapy.

Dr. Khleif was an intramural NIH scientist for about 20 years. While at NCI, he also served as a leader of the Cancer Vaccine Section, leading a nationally active Immune Therapy Program. His laboratory has conducted some of the earliest clinical trials in antigen vaccines and was the first to conduct vaccines against mutant oncogenes. Also, in the past few years some of the discoveries made in his laboratory have been translated into first-in-human immune therapy clinical trials. Furthermore, Dr. Khleif has published several studies on the mechanisms of tumor-induced suppression in animal models and have overcome such inhibition by developing strategies that have been translated into clinical trials. His laboratory has developed models to understand how different kinds of immune therapies can be combined to work synergistically and translated into clinical trials.



## **KAREN KNUDSEN, MBA, PHD**

Professor Emerita, *Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center,*  
Former CEO, *American Cancer Society and ACS CAN*

Karen Knudsen is the former Chief Executive Officer of American Cancer Society and the American Cancer Society Cancer Action Network. She is the first woman to hold that position in either organization.

Prior to joining ACS, Dr. Knudsen served as Executive Vice President of Oncology Services, Jefferson Health and Enterprise Director of its Sidney Kimmel Comprehensive Cancer Center, one of 71 NCI-designated cancer centers in the United States. Previously she was the Hilary Koprowski Endowed Professor of Oncology at Thomas Jefferson University in Philadelphia, Pennsylvania.

Knudsen received her bachelor's degree in biology from the George Washington University, her PhD in molecular biology from the University of California at San Diego in 1996, and her MBA with honors from the Fox School of Business and Management at Temple University. She completed her postdoctoral fellowship training at the Ludwig Institute for Cancer Research, San Diego under the mentorship of Dr. Webster K. Cavenee. She joined the faculty of the University of Cincinnati College of Medicine in 2000, wherein she became a tenured Associate Professor.

In 2007 she joined the Sidney Kimmel Cancer Center at Jefferson Health and founded the cancer center's prostate cancer program. After serving as the Deputy Director of the Sidney Kimmel Cancer Center and the Vice Provost of Thomas Jefferson University, Knudsen accepted the offer to serve as the Enterprise Director of the Sidney Kimmel Cancer Center in 2015, leading the cancer care and cancer discovery mission for Jefferson Health. She is also editor-in-chief, Molecular Cancer Research.

Dr. Knudsen holds leadership roles with some of the most important cancer entities in the nation. She serves on the board of advisors for the NCI and on 12 external advisory boards for NCI-designated cancer centers. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards. She previously served as president of the Association of American Cancer Institutes (AACI), representing the 102 leading cancer centers in North America, and on the board of directors of the American Association for Cancer Research (AACR). Dr. Knudsen was also recognized as one of the 100 Influential Women in Oncology by OncoDaily.



## **EDWARD LICITRA, MD, PhD**

Chief Executive Officer,  
*Astera Health Partners/Astera Cancer*

Edward J. Licitra, MD, PhD received his PhD in Organic Chemistry and Molecular Biology from the Massachusetts Institute of Technology, where he was a National Cancer Institute Predoctoral Fellow. He is a graduate of the University of Medicine & Dentistry of New Jersey, Robert Wood Johnson Medical School along with internship and residency there. Dr. Licitra was the recipient of the Robert Wood Johnson Medical School Research Award and was designated as the Medical School's Department of Internal Medicine Outstanding Resident. He then completed a fellowship in Medical Oncology at the Cancer Institute of New Jersey and was an attending physician at Memorial Sloan Kettering Cancer Center. He then entered private practice in New Jersey in 2006 and has since been developing a high-quality cancer care delivery platform in the community. He is certified by the American Board of Internal Medicine in Medical Oncology. Dr. Licitra has been chosen as a Top Doctor in Oncology & Hematology by New Jersey Monthly magazine. He serves as Chief Executive Officer of Astera Health Partners. He is on the Board of Directors of OneOncology, The Community Oncology Alliance (COA) and the ION Advisory Board.

# Panelist Bios



## **ROBERT LOBERG, PhD**

VP and Lifecycle Leader, Oncology & Genetics  
*Roche Diagnostics*

Robert Loberg is Vice President and Lifecycle leader, Oncology & Genetics at Roche Diagnostics. In his role, Robert oversees development and commercialization of the next generation sequencing & PCR portfolio assay and menu content. In addition, Robert heads the molecular PharmaPartnering & Services Business overseeing the Roche San Jose CAP/CLIA laboratory.

Robert has experience across a range of R&D and commercial activities at both BioPharma and Diagnostics companies. Prior to his joining Roche, Robert spent 13 years at Amgen in various roles ending his time at Amgen leading the Clinical Biomarker and Diagnostics efforts within iR&D. His experience in development, regulatory approval, and market access has led to a record of delivering strategies that support a broad portfolio of pharmaceutical and diagnostic products. With >50 peer-reviewed publications and considerable hands-on lab work, Robert has demonstrated a passion for translational research and its applications in cancer therapeutics.

Robert received his Ph.D in Physiology from the University of Michigan where he also served as an Assistant Professor holding joint appointments in the Department of Internal Medicine and Department of Urology.



## **THOMAS J. LYNCH, JR., MD**

President and Director,  
*Fred Hutch Cancer Center*

Dr. Thomas J. Lynch Jr. is a world-renowned scientist, highly respected oncologist and successful NCI-designated comprehensive cancer center leader. As the President and Director of Fred Hutchinson Cancer Center and holder of the Raisbeck endowed chair, Dr. Lynch brings more than three decades of experience at highly regarded U.S. cancer centers. He has expertise in solid tumor research, precision medicine and discoveries in fundamental biology. Before joining Fred Hutch, Dr. Lynch held leadership roles as CSO at Bristol-Myers Squibb, CEO of Massachusetts General Physicians Organization, director of Yale Cancer Center, physician-in-chief at Yale's Smilow Cancer Hospital, as well as chief of hematology-oncology at Massachusetts General Hospital and professor of medicine at Harvard Medical School. Dr. Lynch is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.



## **SOREN GERMER, PHD**

Senior Vice President Genome Technologies  
*New York Genome Center*

Soren Germer, PhD, leads the sequencing and analytics teams at the New York Genome Center (NYGC), overseeing sequencing production, sequencing analytics, methods development, clinical sequencing and analytics, project management, software engineering, and computational biology. He was appointed to this position in January 2019.

Dr. Germer joined NYGC in March of 2012 as a Sequencing Program Manager and was involved in establishing operations at NYGC at multiple levels, most recently serving as Senior Scientific Director, Sequencing Operations. Prior to NYGC, he was a translational research scientist at Roche Pharmaceuticals, where he led next-generation sequencing lab supporting pre-clinical and early development programs in the areas of virology, oncology, immunology and metabolic diseases. He began his career at Roche Molecular Diagnostics, where he focused on developing new techniques for SNP genotyping and applying them to complex disease research.

Dr. Germer attended the University of Copenhagen and received his PhD from the University of California at Berkeley



## MISHELLENE MCKINNEY, MHA, RN, OCN

Vice President, Clinical Programs,  
*Kaiser Permanente*

Misha McKinney is the Vice President of Clinical Programs for Kaiser Foundation Health Plan, Inc. and Hospitals. She leads the integration of evidence-based, patient-informed interventions and oversees the quality and transformation of care delivery across national clinical programs, including Women and Children's Health, Cancer Care, and Cardiovascular Health. Misha collaborates with Permanente clinical leaders to develop strategies that ensure exceptional service and quality outcomes for Kaiser Permanente members. She also serves as Executive Director of Kaiser Permanente's Care Management Institute. In this role, Misha oversees the Center for Healthcare Delivery and Design, which supports Kaiser Permanente care delivery leaders in identifying and prioritizing opportunities for improvement, testing, and spreading human-centered design practices.

Prior to joining Kaiser Permanente, Misha was the Director of Clinical Pathways and Implementation Science at Roswell Park Comprehensive Cancer Center in Buffalo, NY. She held various positions in nursing administration, including management of the Blood and Marrow Transplant unit, and was Assistant Director of Patient Care Services during her 15-year tenure at Roswell Park.

From 2016 to 2023, Misha moderated and chaired the Clinical Pathways Forum, a community of pathways professionals from cancer centers across the United States and Canada. She is a column writer and serves on the Editorial Board for the *Journal of Clinical Pathways*.

Misha holds a Master of Science degree in Health Administration from Roberts Wesleyan College in Rochester, NY, a Bachelor of Science in Nursing from Simmons College in Boston, MA, and a Bachelor of Arts in International Relations and Economic Development from Mount Holyoke College in South Hadley, MA. She is a graduate of the Implementation Science program at the University of California, San Francisco, and is an Oncology Certified Nurse (OCN). Before beginning her career in nursing, Misha worked for 10 years in financial services, audit, and consulting.



## MIKE MEYER

President and Founder,  
*Meyer Consulting*

Mike Meyer is an entrepreneur, author, health care expert, and founder and host of the CCX Cancer Summit held each year in New York City. He is the President of Meyer Consulting. Early in the pandemic, he coauthored an op-ed in the Wall Street Journal titled Medical Lockdown will Cause a Disease Surge, which proved remarkably accurate. He is known for his work with leading health systems, academic medical centers and health care companies. Over the years, he has built or helped grow multiple health care companies.

Meyer founded Meyer Consulting in 2007 to offer healthcare organizations a consulting firm that has a unique business model encompassing executive search, strategic consulting, and human capital consulting. Meyer's current and former clients include Memorial Sloan Kettering Cancer Center, Mayo Clinic, Blue Cross Blue Shield Association, Horizon Blue Cross Blue Shield NJ, Pfizer, MD Anderson Cancer Center, Summit Medical Group, California Association of Health Plans, WIN Consortium for Personalized Cancer Medicine and numerous other academic centers, large providers, physician groups and other not-for-profit health care organizations.

Meyer's early career was as vice president in charge of the New York office of Amherst Associates, which went public in 1981. He subsequently became a senior partner in Witt Kieffer before founding Meyer Consulting in 2007. Meyer founded Cancer Care at the Crossroads (CCX) Summit in 2016. This one-of-a-kind event brings together senior health care executives from the US and international. In 2019 Meyer Consulting's executive search practice was acquired by Westwood & Wilshire, one of the premier firms in life sciences and technology.

Meyer was a board member of Summit Select, part of Summit Medical Group which merged with CityMD, creating one of the largest private physician groups in the U.S., with support from Warburg Pincus. He cofounded the Institute for Mental Health Research ([www.imhr.org](http://www.imhr.org)) and is a board member of the Human Health and Research Foundation (<http://hhhrf.org>). He has been widely quoted on healthcare, oncology, mental health and retiree topics in healthcare and business publications. He is the author of *Catastrophic Illness and Catastrophic Health Insurance* published by the Heritage Foundation, and coauthor of *Destination Southwest, a Guide to Retiring and Wintering in Arizona*.



## ANAEZE OFFODILE, MD, MPH

Chief Strategy Officer,  
*Memorial Sloan Kettering Cancer Center*

Dr. Offodile - a double board-certified physician with clinical expertise in oncologic reconstruction, a health services researcher with a focus on alternative payment models and care redesign, and a healthcare administrator with management experience in academia - leads strategy efforts and care transformation initiatives at MSK by continuing to develop the core infrastructure, management systems, and processes for enterprise strategy and business development. As CSO, he pilots new initiatives, facilitates alignment on strategic institutional priorities, leverages data sources to cultivate innovative digital analytics and products, develops collaborations with outside groups, and partners with key internal leaders to competitively position MSK for the future. Dr. Offodile also sees patients on a limited basis.

In this role, Dr. Offodile serves as MSK's "futurist," leveraging his deep knowledge of significant trends in clinical care/operations and scientific research into insights and strategies that will propel MSK forward while being mindful of MSK's goal to provide high-quality outcomes and patient experience with reduced cost and enhanced efficiency.

Dr. Offodile joined MSK from the University of Texas MD Anderson Cancer Center, where he served as Enterprise Executive Director for Clinical Transformation since 2018. In that role, he pioneered multiple first-in-oncology programs at the institution to address the operational, financial, and clinical challenges of delivering high-quality, inpatient-level care in a patient's home or community. He was also a member of the Department of Plastic Surgery, where he established a diverse reconstructive practice performing microvascular reconstructive procedures on the breast, extremities, and abdominal wall.

Previously, Dr. Offodile served as Special Advisor to the President of the National Academy of Medicine on activity related to the Regional Vaccine Manufacturing Collaborative and as Policy Advisor to the Group Director of the Patient Care Models Group at the Center for Medicare and Medicaid Innovation. Currently, he is a Nonresident Scholar in Health Policy at the Baker Institute for Public Policy's Center for Health and Biosciences, a nonpartisan think tank at Rice University.

Originally from London, Dr. Offodile holds a Bachelor of Science in biology from Kent State University, a Doctor of Medicine from Columbia University, and a Master of Public Health from the Johns Hopkins Bloomberg School of Public Health. He completed a residency in general surgery at Brigham and Women's Hospital in Boston; a residency in plastic surgery at Lahey Hospital and Medical Center in Burlington, Massachusetts; and a fellowship in reconstructive microsurgery at MD Anderson in Texas.

Dr. Offodile serves on the Editorial Board of *Annals of Surgery*. He was the 2019-2021 Gilbert S. Omenn Fellow at the National Academy of Medicine.



# Panelist Bios



## CINDY PERETTIE

Executive Vice President,  
*Kite Pharma*

Cindy Perettie serves as Executive Vice President of Kite, a Gilead Company, and is responsible for overseeing the cell therapy business.

Cindy joined Kite in 2023 with more than 25 years of scientific and commercial leadership experience in global biopharmaceutical organizations. Most recently, she served as Head of Roche Molecular Lab Solutions where she oversaw the PCR (polymerase chain reaction) and Sequencing Business. Prior to that, she was Chief Executive Officer at Foundation Medicine. Before joining Foundation Medicine, Cindy was Head of Global Oncology Strategy at Roche's Oncology Unit. In 2012, Cindy joined Sarah Cannon Research Institute as President of Global Development Innovations where she gained invaluable insights into the day-to-day care of people living with cancer. She started her career at Johns Hopkins University as a senior research associate.

She holds an MBA from Saint Mary's College of California and a bachelor's degree in biology with a minor in chemistry from The State University of New York at Potsdam.



## DAVID RHEW, MD

Global Chief Medical Officer, VP Healthcare, Worldwide Commercial,  
*Microsoft*

Dr. David C. Rhew is the Global Chief Medical Officer (CMO) and Vice President (VP) of Healthcare for Microsoft. He is the Chairman of the Health and Fitness Technology Division for the Consumer Technology Association and serves on CTA's Board of Industry Leaders. He co-holds six U.S. technology patents that enable authoring, mapping, and integration of clinical decision support into the electronic health record. David is currently an Adjunct Professor at the Stanford University School of Medicine.

Dr. Rhew received his Bachelors of Science degrees in computer science and cellular molecular biology from the University of Michigan. He received his MD degree from Northwestern University and completed internal medicine residency at Cedars-Sinai Medical Center. He completed fellowships in health services research at Cedars-Sinai and infectious diseases at the University of California, Los Angeles.

He has served as CMO and VP for Samsung; Senior Vice President and CMO at Zynx Health Incorporated; clinician/researcher in the Division of Infectious Diseases at the VA Greater Los Angeles Healthcare System; and Associate Clinical Professor of Medicine at UCLA. Dr. Rhew has served on the National Quality Forum's (NQF) Executive Committee for Consensus Standards and Approval.



## JONATHAN ROCKOFF

Health Business Editor and Deputy Coverage Chief for Health and Science, *The Wall Street Journal*

Jonathan D. Rockoff is the Health Business Editor at The Wall Street Journal, as well as its Deputy Coverage Chief for Health and Science. Based in New York City, he edits a group of reporters that write about pharmaceutical companies, health insurers and hospitals, while helping oversee science, medicine and public-health reporting. Previously for the newspaper, Jonathan reported on the pharmaceutical and biotechnology industries. He was a member of a team of reporters that was a finalist for the Pulitzer Prize for their coverage of drug pricing. Jonathan has also worked at The Baltimore Sun and The Providence Journal. He is a graduate of Princeton University and the University of Virginia School of Law.



## **NORMAN SHARPLESS, MD**

Professor of Cancer Policy and Innovation,  
*UNC-Chapel Hill*,  
Co-CEO, *Jupiter BioVentures*,  
former Director of *NCI* and former acting Commissioner of *FDA*

Dr. Sharpless is a physician, scientist, entrepreneur and former federal official, serving as Director of the National Cancer Institute from 2017 to 2022, and as Acting Commissioner of the US Food and Drug Administration in 2019. Prior to government, Dr. Sharpless was the Wellcome Distinguished Professor of Medicine and Director of the Lineberger Comprehensive Cancer Center at the University of North Carolina School of Medicine. He is on the boards of G1 Therapeutics, Karius Inc, Nucleus Radiopharma, the Eshelman Institute for Innovation, the CEO Roundtable on Cancer, and the American Cancer Society; and is the co-Founder and Managing Director of Jupiter BioVentures. He is the Professor of Cancer Policy and Innovation at the University of North Carolina School of Medicine and is a member of the American Association for Cancer Research Academy, the Association of American Physicians, the American Society for Clinical Investigation, and the National Academy of Medicine.



## **LILLIAN SIU, MD, FRCPC**

Professor, *University of Toronto*; Medical Oncologist, Director, Phase I Program, BMO Chair in Precision Genomics, *Princess Margaret Cancer Centre*

Dr. Siu is a senior medical oncologist at Princess Margaret Cancer Centre since 1998 and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at Princess Margaret Cancer Centre and holds the BMO Chair in Precision Genomics (2016-2026). She is also the Clinical Lead for the Tumor Immunotherapy Program at Princess Margaret Cancer Centre. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016); she also served on the American Association for Cancer Research (AACR) Board of Directors for a three-year term (2017-2020).

Dr. Siu's major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies. She is the Principal Investigator of a phase I cooperative agreement UM1 award sponsored by the United States National Cancer Institute. In addition to her active research in early phase clinical trials, she has been leading genomics initiatives and immuno-oncology trials at the Princess Margaret Cancer Centre. Together, the three programs of drug development, cancer genomics and tumor immunotherapy form a triad of synergy that supports the institution's core vision to deliver precision cancer medicine. Internationally, Dr. Siu was the recipient of the US NCI Michael C. Christian Award in Oncology Drug Development in 2010. She has been awarded the TAT 2020 Honorary Award for contributions in the development of anticancer drugs. Dr. Siu has published over 370 peer-reviewed manuscripts, and she is currently the co-Editor-in-Chief for AACR's newest journal *Cancer Research Communications* and is on the editorial board for *Cell and Cancer Cell*.



## **GLEN STETTIN, MD**

Senior Vice President and Chief Innovation Officer,  
*Evernorth/CIGNA*

Dr. Glen Stettin is a champion for new solutions to our clients' and patients' biggest healthcare challenges - affordability, poor care and outcomes, poor experiences and the inequity that amplifies these challenges for members of disadvantaged and marginalized communities. For more than 25 years, Dr. Stettin has been leading innovation, clinical and technical development, and advancing analytic approaches for understanding these big challenges and prompting action on behalf of the clients and patients of the health services businesses that have become Evernorth.

As Chief Innovation Officer, Dr. Stettin applies his expertise in diagnostic and treatment strategies, the behavioral sciences and data science to address the most complex and challenging issues in the coverage and delivery of quality health care. Dr. Stettin's team includes the leaders of the Evernorth Research Institute, which focuses on deeply understanding the big healthcare challenges and approaches to solving them, Evernorth's chief patient and physician experience officers, the heads of our advanced data and analytic capabilities and services, and Evernorth Labs, which brings together more than 200 experts, including physicians, nurses, pharmacists, data scientists and software engineers, across sites in three cities, designed for innovation and collaboration, to focus on solving client and patient pain points, through rapid prototyping, in-house development and partnerships with clients and industry innovators.

Dr. Stettin joined the Cigna Corporation in 2018 through the acquisition of Express Scripts, where he had served as senior vice president & chief innovation officer. He came to Express Scripts in 2012 with the acquisition of Medco, where he served as chief medical officer and, for 17 years, in leadership positions in nearly every corporate function with exception of finance, legal and human resources.

Dr. Stettin completed his residency in internal medicine at the University of California, San Francisco, where he also served as medical chief resident and assistant chief of the medical service, Moffitt Hospital, fellow in cardiology and Robert Wood Johnson Clinical Scholar (UCSF/Stanford). He earned his medical and bachelor's degrees through the joint accelerated program of the Medical College of Pennsylvania and Lehigh University.

# Panelist Bios



## ZHEN SU, MD, MBA

CEO,  
*Marengo Therapeutics*

As CEO of Marengo Therapeutics and a director of the company's board, Zhen Su brings more than two decades of experiences as a physician-scientist and business executive, with expertise in building and leading both R&D and commercial organizations. Prior to joining Marengo, Zhen served as Senior Vice President and Global Head of Oncology for Merck KGaA, where he led the franchise's turnaround to achieve double-digit organic growth and an annual revenue above €1B. In this role, he also successfully expanded the oncology portfolio including key alliance partnerships with Pfizer (\$2.8B), GSK (\$4.2B), and Debiopharm (\$1.1B). In his earlier role as Chief Medical Officer of EMD Serono and head of its Oncology Medical division, he played an instrumental role in 8 major regulatory approvals across different indications for Bavencio®, Tepmetko®, Erbitux®, and Mavenclad®. He also held leadership roles with increasing responsibilities at Sanofi Oncology and GSK. Before his industry career, Zhen served on the faculty of Duke University, where he led early clinical studies focusing on mRNA-based and cell-based immunotherapy, and then the University of Florida, where he was the director of the Cell and Gene Therapy program. He is the author of more than 60 publications in immuno-oncology and targeted oncology.

Zhen earned his M.D. from the Technical University of Dresden, completed his post-doctoral training in tumor immunology at Duke University, and received an MBA from the University of Toronto.



## RICHARD SULLIVAN, MD, PhD

Director, *Institute for Cancer Policy*,  
Professor of Cancer & Global Health, *King's College London*

Richard Sullivan is Professor of Cancer and Global Health at King's College London and Guy's Comprehensive Cancer Centre. He is director of the Institute of Cancer Policy and Director of the Centre for Conflict & Health Research at King's. He is an NCD advisor to World Health Organisation and World Bank. His global cancer research programs cover cancer systems strengthening, financing, political economy, global cancer surgery particularly virtual reality-enhanced surgical simulation training, as well as studies into social welfare and cancer care in conflict. He also directs a number of major research programs in conflict and health with a special focus on the Middle East, including Health Security Intelligence, Global Health Security and health systems strengthening in conflict. Professor Sullivan trained in surgery (urology) gaining his PhD in Biochemistry from University College London. Richard was formally Clinical Director of Cancer Research UK for nearly ten years and is a surgeon by background.



## GLEN TULLMAN

Chief Executive Officer,  
*Transcarent*

Glen Tullman is the Chief Executive Officer of Transcarent, the first comprehensive, consumer-directed health and care platform that makes it easy for people to access high-quality, affordable health and care. Transcarent is transforming healthcare with WayFinding, an experience powered by clinicians and generative AI where Members can "Just Ask Transcarent" to instantly get trusted health and benefits navigation, take the next step with personalized clinical guidance, and access on-demand care delivery.

Tullman is the former Executive Chairman, Chief Executive Officer, and Founder of Livongo Health, the first at-scale consumer digital health company to truly empower people with chronic conditions to live better and healthier lives using data science. In his final year, Glen led Livongo through the largest consumer digital health Initial Public Offering in history, a secondary offering, a convertible debt offering that raised over \$550 million, and the industry's largest merger to date between Livongo and Teladoc Health, valuing Livongo at \$18.5 billion and beginning a new era of consumer-directed virtual care. A visionary leader and entrepreneur, Tullman previously ran two other public companies that changed the way health care is delivered. During his time as Chief Executive Officer of Allscripts, the Company was the leading provider of electronic prescribing, practice management, and electronic health records for physician practices. Glen led Allscripts IPO and Secondary offerings. Prior to Allscripts, he was Chief Executive Officer of Enterprise Systems, the leading resource management systems for hospitals, which he also took public and then sold to McKesson/HBOC. Before entering healthcare, Glen served as President and COO of CCC Information Systems, a provider of computerized systems for the property and casualty insurance sector.

Glen is also one of two Founding Partners at 7wire Ventures, one of the highest-returning venture capital funds in Illinois. He is the author of *On Our Terms: Empowering the New Health Consumer*, in which he proposes new solutions to address the chronic condition epidemic facing our country.

A strong proponent of philanthropy, Glen was honored in 2019 with a Robert F. Kennedy Human Rights Ripple of Hope Award for his career focused on improving the safety, empathy, and efficiency of our healthcare system. He also serves as a Life Director of the Illinois Chapter of Breakthrough T1D, the leading organization advancing life-changing breakthroughs for Type 1 Diabetes.

Glen has three amazing children and three grandchildren who inspire him every day.



## SUNIL VERMA, MD

SVP Global Head of Oncology Franchise,  
*AstraZeneca*

Doctor Sunil Verma serves as the Global Head, Oncology Franchise helping to oversee the global strategy of our Oncology portfolio and our work to transform cancer care in partnership with health systems globally. Prior to joining AstraZeneca, Doctor Verma worked as a Medical Oncologist, specializing in breast cancer and lung cancer care. He has had a prolific impact on Cancer care and has helped to advance the development of a number of pivotal therapies that have shaped cancer care globally. He held positions as Professor and Head of the Department of Oncology at the University of Calgary, along with serving as the Medical Director of the Tom Baker Cancer Centre.



## JEDD WOLCHOK, MD, PhD

Meyer Director of, *the Sandra and Edward Meyer Cancer Center* and  
Professor of Medicine, *Weill Cornell Medicine*

Dr. Jedd D. Wolchok is the Meyer Director of the Sandra and Edward Meyer Cancer Center and a professor of medicine at Weill Cornell Medicine. Prior to joining Weill Cornell Medicine in 2022, he was the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation; Chief, Immuno-Oncology Service, Human Oncology and Pathogenesis Program; director, Parker Institute for Cancer Immunotherapy; and associate director, the Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center.

Dr. Wolchok has been at the forefront of cancer immunotherapy and is renowned for leading the clinical trials that led to the first FDA-approved checkpoint inhibitor immunotherapy, the anti-CTLA-4 antibody ipilimumab. He continues to lead clinical trials aimed at expanding immunotherapy's benefits to more patients. He also conducts research that focuses on the GITR and OX40 pathways, as well as how some immune cells, known as myeloid-derived suppressor cells, influence anti-tumor immune responses.

In addition to his role as an associate director of CRI's Scientific Advisory Council, Dr. Wolchok serves on the CLIP Grant Review Committee and is also a member of CRI's Clinical Leadership Committee.



Meyer Consulting is an international health care consulting firm that brings leading experts together in collaborative settings to build better health care solutions.





MEYER CONSULTING  
Phone (406) 531-5505

[www.meyerconsultinginc.com](http://www.meyerconsultinginc.com)